Four Atlas Antibodies TripleA Polyclonals used in the study about IDH mutation
November, 2021 (Key Laboratory of Ministry of Education for Medicinal Plant Resource and Natural Pharmaceutical Chemistry, China)
IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Diffusely infiltrating gliomas are classified depending on mutations in isocitrate dehydrogenase (IDH) into IDH-wild-type and IDH-mutated gliomas.
This study published in Neuro Oncology reports that the IDH mutation status is associated with distinct vascular gene expression signatures: IDH-wild-type low-grade gliomas vessels are molecularly distinct from the vasculature of IDH-mutated low-grade gliomas indicative of ongoing angiogenesis and vascular remodeling.
The results implicate that IDH-wild-type low-grade gliomas may respond differently to anti-angiogenic therapy.
Furthermore, since TGFβ / hypoxia signaling contributes to the altered vascular gene expression, they may represent potential targets for normalizing the vasculature in IDH-wild-type low-grade gliomas.
Four of our TripleA Polyclonals are used in the study: